ANTX (AN2 Therapeutics) Buyback Yield %: -24.06 (As of Jul. 08, 2026)


ANTX AN2 Therapeutics Inc ANTX
22 GF Score
Price $4.41
! 3 Warning Signs
View Full Analysis

What is AN2 Therapeutics Buyback Yield %?

AN2 Therapeutics ANTX +2.56% 22 Buyback Yield % is -24.06 as of Jul. 08, 2026. GuruFocus rates ANTX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 741 Biotechnology companies, AN2 Therapeutics ranks worse than 71.52% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

AN2 Therapeutics's current buyback yield was -24.06%.

AN2 Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for AN2 Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AN2 Therapeutics Buyback Yield % Chart

AN2 Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial 0.00 -38.05 -13.87 0.00 0.00

AN2 Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -30.28

ANTX vs OKUR, KRRO, LENZ: Buyback Yield % Comparison

For the Biotechnology subindustry, AN2 Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AN2 Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where AN2 Therapeutics's Buyback Yield % falls into.


ANTX
22GF Score
AN2 Therapeutics Inc ANTX
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AN2 Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

AN2 Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 31.25082
=0.00%

AN2 Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 37.266) / 123.07212
=-30.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -24.06 mean?
AN2 Therapeutics (ANTX) has a Buyback Yield % of -24.06 as of Jul. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on AN2 Therapeutics and its competitors. According to the industry distribution chart, AN2 Therapeutics ranks #530 out of 741 companies in the Biotechnology industry, placing it in the top 71.5%.
Is AN2 Therapeutics' Buyback Yield % too high?
AN2 Therapeutics' current Buyback Yield % is -24.06. Based on the distribution chart, AN2 Therapeutics ranks #530 out of 741 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AN2 Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does AN2 Therapeutics' Buyback Yield % compare to OKUR and KRRO?
According to the Biotechnology industry distribution chart, AN2 Therapeutics ranks #530 out of 741 companies for Buyback Yield %. This places AN2 Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on AN2 Therapeutics and its competitors. AN2 Therapeutics's current Buyback Yield % is -24.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AN2 Therapeutics stock overvalued right now?
AN2 Therapeutics (ANTX) has a current Buyback Yield % of -24.06. The current Buyback Yield % is -24.06. AN2 Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For AN2 Therapeutics (ANTX), the current Buyback Yield % is -24.06 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AN2 Therapeutics Business Description

Address 1300 El Camino Real, Suite 100, Menlo Park, CA, USA, 94025
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
22GF Score

Get the complete analysis for ANTX

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.41
Price